Request Demo
Last update 28 Jun 2025
Teriparatide biosimilar (Dongguan Baolijian Bioengineering)
Last update 28 Jun 2025
Overview
Basic Info
Drug Type Recombinant polypeptide, Biosimilar |
Synonyms 重组人甲状旁腺激素（1-34）(东莞宝丽健生物) |
Target |
Action agonists, stimulants |
Mechanism PTH1R agonists(Parathyroid hormone receptor agonists), Osteogenesis stimulants, Parathyroid hormone replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 4953
The sequence is quoted from: *****
Related
3
Clinical Trials associated with Teriparatide biosimilar (Dongguan Baolijian Bioengineering)CTR20131313
PTH（1-34）治疗绝经后妇女骨质疏松症安全性和有效性的随机、开放、阳性药对照、多中心临床研究
[Translation] A randomized, open, active-controlled, multicenter clinical study on the safety and efficacy of PTH (1-34) in the treatment of osteoporosis in postmenopausal women
CTR20150391
评价PTH（1-34）治疗绝经后妇女骨质疏松症安全性和有效性的随机、开放、阳性药平行对照、多中心临床研究
[Translation] A randomized, open, active drug parallel controlled, multicenter clinical study to evaluate the safety and efficacy of PTH (1-34) in the treatment of osteoporosis in postmenopausal women
CTR20150392
评价注射用重组人甲状旁腺素（1-34）在中国健康人群的安全性和药代动力学特征
[Translation] To evaluate the safety and pharmacokinetic characteristics of recombinant human parathyroid hormone (1-34) for injection in healthy Chinese population
100 Clinical Results associated with Teriparatide biosimilar (Dongguan Baolijian Bioengineering)
Login to view more data
100 Translational Medicine associated with Teriparatide biosimilar (Dongguan Baolijian Bioengineering)
Login to view more data
100 Patents (Medical) associated with Teriparatide biosimilar (Dongguan Baolijian Bioengineering)
Login to view more data
100 Deals associated with Teriparatide biosimilar (Dongguan Baolijian Bioengineering)
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Osteoporosis, Postmenopausal | Phase 3 | China | 22 Jun 2009 | |
| Hypogonadism | Phase 2 | China | 12 Apr 2007 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free